Fructooligosaccharides (FOS) के लिए Irritable Bowel Syndrome (IBS)
D अनुसंधान केवल प्रारंभिक शोध उपलब्ध है (प्रयोगशाला अध्ययन, केस रिपोर्ट)।Mixed results. Low doses may help (5 g) but higher doses can worsen bloating due to rapid fermentation.
निष्कर्ष
Mixed results. Low doses may help (5 g) but higher doses can worsen bloating due to rapid fermentation.
Key Study Findings
जनसंख्या: Commercially available pasta products (analytical study)
जनसंख्या: IBS patients (Rome IV criteria)
जनसंख्या: Laboratory food science study (no human subjects)
जनसंख्या: IBS patients
जनसंख्या: None
जनसंख्या: Irritable bowel syndrome with diarrhea and antibiotic-associated diarr
Key Statistics
2
अध्ययन
150
प्रतिभागी
Mixed
ग्रेड
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
सामान्य रूप से उपयोग की जाने वाली खुराकें
- general:
- 2-10 g/day
- prebioticeffect:
- 5-8 g/day for bifidogenic effect
- constipationsupport:
- 5-10 g/day
अधिकतम सीमा: Well-tolerated up to 20 g/day; start low to avoid excess gas
अनुसंधान में अध्ययन की गई खुराकें
| खुराक | अवधि | प्रभाव | N |
|---|---|---|---|
| None | -- | Neutral | -- |
| None | 12 weeks | Positive | 9 |
| None | -- | Positive | -- |
| None | 12 weeks | Positive | -- |
| None | -- | Mixed | -- |
| 350 mg | 3.0 weeks | Positive | 54 |
| None | -- | Mixed | -- |
| None | -- | Negative | -- |
सेवन का सर्वोत्तम समय: With meals; divide doses throughout the day
Safety & Side Effects
रिपोर्ट किए गए दुष्प्रभाव
- ⚠ Gas, bloating, and flatulence (dose-dependent; more common above 10 g/day)
- ⚠ Abdominal cramping at higher doses
- ⚠ May worsen IBS symptoms in FODMAP-sensitive individuals
- ⚠ Loose stools at excessive doses
ज्ञात अंतःक्रियाएँ
- ● Other FODMAPs (cumulative fermentation effect in sensitive individuals)
- ● Blood sugar-lowering medications (FOS may modestly affect glycemic response)
- ● Calcium supplements (FOS may enhance calcium absorption)
सहनीय अधिकतम सेवन: Well-tolerated up to 20 g/day; start low to avoid excess gas
कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।
Frequently Asked Questions
Does Fructooligosaccharides (FOS) help with Irritable Bowel Syndrome (IBS)?
How much Fructooligosaccharides (FOS) should I take for Irritable Bowel Syndrome (IBS)?
Are there side effects of Fructooligosaccharides (FOS)?
How strong is the evidence for Fructooligosaccharides (FOS) and Irritable Bowel Syndrome (IBS)?
Related Evidence
इसके लिए अन्य सामग्री Irritable Bowel Syndrome (IBS)
Fructooligosaccharides (FOS) अन्य स्वास्थ्य स्थितियों के लिए
References
- [1] Aleksandra M Torbica et al.. Foods. 2025. FODMAP Profile of Wholegrain Pasta. doi:10.3390/foods14040667 PubMed
- [2] Aleksandra M Torbica et al.. Foods. 2025. Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers. doi:10.3390/foods14040582 PubMed
- [3] Line Graser Jensen et al.. Gastroenterol Res Pract. 2025. Modification of the Low FODMAP Diet Is Feasible in the Treatment of Irritable Bowel Syndrome: A Randomised Crossover Study. doi:10.1155/grp/4152978 PubMed
- [4] Anita Gąsiorowska et al.. J Clin Med. 2024. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel … doi:10.3390/jcm14010006 PubMed
- [5] Justin L Guice et al.. Front Nutr. 2023. Microbial inulinase promotes fructan hydrolysis under simulated gastric conditions. doi:10.3389/fnut.2023.1129329 PubMed
- [6] V N Drozdov et al.. Vopr Pitan. 2023. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea … doi:10.33029/0042-8833-2023-92-4-92-103 PubMed
- [7] Ashinshana U Illippangama et al.. Carbohydr Polym. 2022. Inulin as a functional ingredient and their applications in meat products. doi:10.1016/j.carbpol.2021.118706 PubMed
- [8] J B J Kamphuis et al.. FASEB J. 2022. Increased fermentable carbohydrate intake alters colonic mucus barrier function through glycation processes and increased mast cell counts. doi:10.1096/fj.202100494RRR PubMed
- [9] Anita Gąsiorowska et al.. J Clin Med. 2022. Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of … doi:10.3390/jcm11216587 PubMed
- [10] Susie Jung et al.. Nutrients. 2022. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic in Patients with Functional Diarrhea and High Fecal … doi:10.3390/nu14235017 PubMed
- [11] Diego Currò. Expert Rev Gastroenterol Hepatol. 2022. Current evidence on the therapeutic use of fiber in irritable bowel syndrome. doi:10.1080/17474124.2021.1924057 PubMed
- [12] Marcel Skejovic Joehnke et al.. Food Chem X. 2021. Nutritional and anti-nutritional properties of lentil (Lens culinaris) protein isolates prepared by pilot-scale processing. doi:10.1016/j.fochx.2020.100112 PubMed
- [13] Johannes Pitsch et al.. Foods. 2021. FODMAP Fingerprinting of Bakery Products and Sourdoughs: Quantitative Assessment and Content Reduction through Fermentation. doi:10.3390/foods10040894 PubMed
- [14] Barbara Skrzydło-Radomańska et al.. Nutrients. 2020. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant … doi:10.3390/nu12071999 PubMed
- [15] Tobias Pöhnl et al.. J Agric Food Chem. 2018. Impact of Cultivation Method and Cultivar Selection on Soluble Carbohydrates and Pungent Principles in Onions ( Allium cepa L.). doi:10.1021/acs.jafc.8b05018 PubMed
- [16] F Azpiroz et al.. Neurogastroenterol Motil. 2017. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double … doi:10.1111/nmo.12911 PubMed
- [17] Jennifer Erickson et al.. Nutr J. 2017. Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial. doi:10.1186/s12937-017-0256-3 PubMed
- [18] V I Pilipenko et al.. Vopr Pitan. 2013. [Contemporary dietotherapy of the irritable bowel syndrome]. PubMed
- [19] M Olesen et al.. Am J Clin Nutr. 2000. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. doi:10.1093/ajcn/72.6.1570 PubMed
FDA अस्वीकरण: इन कथनों का Food and Drug Administration द्वारा मूल्यांकन नहीं किया गया है। इस वेबसाइट पर उत्पादों और जानकारी का उद्देश्य किसी बीमारी का निदान, उपचार, इलाज या रोकथाम नहीं है। प्रस्तुत साक्ष्य ग्रेड प्रकाशित पीयर-रिव्यूड अनुसंधान के हमारे विश्लेषण पर आधारित हैं और चिकित्सा सलाह नहीं हैं। कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।